Women's Health Initiative

Institution(s): 
Fred Hutchinson Cancer Research Center
Approx. Sample Size: 
11,100WGS, 1400RNA (ph4), 1400Metab (ph5), 1400Methyl (ph5)

Project:

PI: 
Charles Kooperberg
Contact: 
Starting Phase: 
Phase 2
Phases Involved: 
2
4
5
Co-PI: 
Alex Reiner
Phenotype Liaison: 
Data Set contact(s): 
Short Name: 
WHI
Omics Center(s) Phase 2: 
Broad Institute Genomics Platform
Omics Center(s) Phase 4: 
Broad Institute Genomics Platform
Type of Omics: 
WGS
RNASeq
Metabolomics
Methylomics
External Funding: 
TOPMed Accession #: 
Omics Center(s) Phase 5: 
Broad Institute Metabolomics Platform
Keck MGC
Description: 

The Women’s Health Initiative (WHI) cohort. The WHI is a prospective national health study focused on identifying optimal strategies for preventing chronic diseases that are the major causes of death and disability in postmenopausal women [refs]. The WHI initially recruited 161,808 women between 1993 and 1997 with the goal of including a socio-demographically diverse population with racial/ethnic minority groups proportionate to the total minority population of US women aged 50-79 years. The WHI consists of two major parts: a set of randomized Clinical Trials and an Observational Study. The WHI Clinical Trials (CT; N=68,132) includes three overlapping components, each a randomized controlled comparison: the Hormone Therapy Trials (HT), Dietary Modification Trial, and Calcium and Vitamin D Trial. A parallel prospective observational study (OS; N = 93,676) examined biomarkers and risk factors associated with various chronic diseases. While the HT trials ended in the mid-2000s, active follow-up of the WHI-CT and WHI-OS cohorts has continued for over 25 years, with the accumulation of large numbers of diverse clinical outcomes, risk factor measurements, medication use, and many other types of data.